Nothing Special   »   [go: up one dir, main page]

EA201791238A1 - Способы и композиции, в которых используются варианты полипептидов klotho - Google Patents

Способы и композиции, в которых используются варианты полипептидов klotho

Info

Publication number
EA201791238A1
EA201791238A1 EA201791238A EA201791238A EA201791238A1 EA 201791238 A1 EA201791238 A1 EA 201791238A1 EA 201791238 A EA201791238 A EA 201791238A EA 201791238 A EA201791238 A EA 201791238A EA 201791238 A1 EA201791238 A1 EA 201791238A1
Authority
EA
Eurasian Patent Office
Prior art keywords
optionally
compositions
methods
options
sklotho
Prior art date
Application number
EA201791238A
Other languages
English (en)
Inventor
Дунлинь Го
Чиквенду Ибебунджо
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201791238A1 publication Critical patent/EA201791238A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)

Abstract

Настоящее изобретение направлено на композиции и способы, имеющие отношение к варианту или фрагменту α-sKlotho, в котором от 1 до вплоть приблизительно 20 аминокислот были делетированы с С-конца, необязательно также имеющему мутации в V563 и/или K795. Настоящее изобретение также имеет отношение к варианту или фрагменту полипептида α-sKlotho, имеющему мутации в V563 и/или K795, причем этот вариант или фрагмент полипептида является полноразмерным, или необязательно от 1 до вплоть приблизительно 20 аминокислот были делетированы с С-конца. Настоящее изобретение также имеет отношение к слитым полипептидам, включающим: (а) α-sKlotho, в котором от 1 до вплоть приблизительно 20 аминокислот были делетированы с С-конца, необязательно также имеющий мутации в V563 и/или K795; (b) линкер и (с) FGF23, необязательно имеющий мутацию в R179, С206 и/или С244, или (с) сывороточный альбумин.
EA201791238A 2014-12-04 2015-12-02 Способы и композиции, в которых используются варианты полипептидов klotho EA201791238A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087516P 2014-12-04 2014-12-04
PCT/IB2015/059294 WO2016088059A1 (en) 2014-12-04 2015-12-02 Methods and compositions using klotho variant polypeptides

Publications (1)

Publication Number Publication Date
EA201791238A1 true EA201791238A1 (ru) 2018-02-28

Family

ID=55024183

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791238A EA201791238A1 (ru) 2014-12-04 2015-12-02 Способы и композиции, в которых используются варианты полипептидов klotho

Country Status (12)

Country Link
US (2) US10654909B2 (ru)
EP (1) EP3227319B1 (ru)
JP (1) JP2017537926A (ru)
KR (1) KR20170084332A (ru)
CN (1) CN107810201A (ru)
AU (1) AU2015356643B2 (ru)
BR (1) BR112017011398A2 (ru)
CA (1) CA2969307A1 (ru)
EA (1) EA201791238A1 (ru)
MX (2) MX2017007303A (ru)
TW (1) TW201628641A (ru)
WO (1) WO2016088059A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3031839B1 (fr) 2015-01-19 2020-03-13 Areva Stockage D'energie Systeme electrique comprenant un empilement de cellules electrochimiques et procede de pilotage de ce systeme
EP3253403B1 (en) 2015-02-06 2021-09-01 The Regents of The University of California Methods and compositions for improved cognition
CN109996555A (zh) * 2016-11-22 2019-07-09 克洛索治疗有限公司 新颖重组klotho蛋白及其组合物和方法
CA3069143A1 (en) 2017-07-06 2019-01-10 Yale University Compositions and methods for treating or preventing endocrine fgf-linked diseases
WO2019118620A1 (en) * 2017-12-13 2019-06-20 Yale University Compositions and methods for treating or preventing endocrine fgf23-linked diseases
US20210054355A1 (en) * 2018-01-12 2021-02-25 New York University Soluble alpha-klotho proteins, protein fragments, and uses thereof
US20220008520A1 (en) * 2018-11-21 2022-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for reducing age-related striated muscle and cognitive decline
CN112695049A (zh) * 2020-08-20 2021-04-23 山东兴瑞生物科技有限公司 修饰间充质干细胞的融合基因、质粒、修饰得到干细胞及制备方法
CN112915193B (zh) * 2021-03-05 2022-09-13 南方医科大学南方医院 Kp-1在制备治疗慢性肺病的药物中的用途
CN112915192B (zh) * 2021-03-05 2022-10-25 南方医科大学南方医院 Kp-1在制备治疗慢性肝病的药物中的用途
EP4395807A2 (en) * 2021-09-03 2024-07-10 The UAB Research Foundation Fibroblast growth factor 23 modulating compounds
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
EP0550436A1 (en) 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
US5387742A (en) 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
US5408038A (en) 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5541094A (en) 1992-09-25 1996-07-30 E. I. Du Pont De Nemours And Company Glyoxylic acid/aminomethylphosphonic acid mixtures prepared using a microbial transformant
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US6187992B1 (en) 1994-12-05 2001-02-13 Merck & Co., Inc. Transgenic mouse having a disrupted amyloid precursor protein gene
EP0850051A2 (en) 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US6194177B1 (en) 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. DNA encoding a hybrid heterodimeric protein
AU709323B2 (en) 1996-03-15 1999-08-26 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neuropathy by administering selegiline
US6358752B1 (en) 1996-09-27 2002-03-19 Cornell Research Foundation, Inc. Liposome-enhanced test device and method
JP4112627B2 (ja) 1996-12-26 2008-07-02 社団法人芝蘭会 新規ポリペプチド、新規ｄｎａおよび新規抗体
US6127598A (en) 1997-07-25 2000-10-03 The Regents Of The University Of California NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
AU3463699A (en) 1998-04-03 1999-10-25 Phylos, Inc. Addressable protein arrays
US7060479B2 (en) 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
EP1171778B1 (en) 1999-04-22 2006-03-01 Liposcience, Inc. Nmr-method for determining the risk of developing type 2 diabetes
US6687749B1 (en) 1999-06-30 2004-02-03 Microsoft Corporation Methods and systems for reporting and resolving support incidents
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US6406853B1 (en) 1999-12-23 2002-06-18 The Regents Of The University Of California Interventions to mimic the effects of calorie restriction
JP2005508131A (ja) 2000-02-15 2005-03-31 アムジェン インコーポレイテッド 線維芽細胞成長因子−２３分子およびその使用
JP2006238894A (ja) 2000-02-15 2006-09-14 Amgen Inc 線維芽細胞成長因子−２３分子およびその使用
US20060160181A1 (en) 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
US20020082205A1 (en) 2000-03-08 2002-06-27 Nobuyuki Itoh Human FGF-23 gene and gene expression products
JP2004504063A (ja) 2000-07-19 2004-02-12 アドバンスド　リサーチ　＆　テクノロジー　インスティテュート 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法
AU2002243750A1 (en) 2001-01-30 2002-08-12 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide molecules
US7588757B2 (en) 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
AU2002302581A1 (en) 2001-04-26 2002-11-11 Geneprot, Inc. Human fibroblast growth factor-related compositions
EP1327443A1 (en) 2001-12-21 2003-07-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic or preventing agent for the diseases caused by a decrease in the expression level of the klotho protein
US20050004348A1 (en) 2002-12-23 2005-01-06 Miyamoto Ken-Ichi Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US20170233446A1 (en) 2008-01-28 2017-08-17 Novartis Ag Methods and compositions using klotho-fgf fusion polypeptides
WO2009117622A2 (en) 2008-03-19 2009-09-24 Ambrx, Inc. Modified fgf-23 polypeptides and their uses
NZ592009A (en) 2008-10-10 2012-11-30 Amgen Inc Fgf21 mutants and uses thereof
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
WO2013027191A1 (en) * 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules

Also Published As

Publication number Publication date
US10654909B2 (en) 2020-05-19
AU2015356643B2 (en) 2019-01-24
US20180037623A1 (en) 2018-02-08
AU2015356643A1 (en) 2017-06-22
WO2016088059A1 (en) 2016-06-09
EP3227319B1 (en) 2019-11-27
JP2017537926A (ja) 2017-12-21
CN107810201A (zh) 2018-03-16
US20200362015A1 (en) 2020-11-19
KR20170084332A (ko) 2017-07-19
MX2017007303A (es) 2017-08-25
EP3227319A1 (en) 2017-10-11
MX2021000030A (es) 2021-03-25
CA2969307A1 (en) 2016-06-09
TW201628641A (zh) 2016-08-16
BR112017011398A2 (pt) 2018-04-03

Similar Documents

Publication Publication Date Title
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
MX2017006866A (es) Pares de unión para producción de péptidos.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
PH12019500596A1 (en) Recombinant binding proteins and their use
EA201691111A1 (ru) Химерные белки фактора viii и их применение
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
RU2021134101A (ru) Модифицированная j-цепь
TW201613958A (en) MIC-1 fusion proteins and uses thereof
EA201491051A1 (ru) Вакцины против вируса гриппа и их применения
PH12015502612B1 (en) Influenza virus vaccines and uses thereof
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
MX343386B (es) Proteinas de fusion portadoras de peptido como vacunas para alergia.
EA201491277A1 (ru) Противораковый слитый белок
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2017015927A (es) Fragmentos mutantes de proteina ras.
RU2017132689A (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
EA201792362A8 (ru) Композиции и способы для лечения целиакии спру
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
NZ724196A (en) Uti fusion proteins
PE20180162A1 (es) Polipeptidos dirigidos a la fusion de vih
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
EA201990255A1 (ru) Фактор свертывания крови vii пролонгированного действия и способы его получения
WO2015134833A3 (en) Therapeutic proteins for treating cancers and methods for using such proteins
EA202092106A2 (ru) Модифицированные полипептиды fgf-21 и их применение